Panel Reverses Patent Board Obviousness Ruling In Tarceva Case

Mealey's (October 7, 2019, 12:37 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Oct. 4 disagreed with a determination by the Patent Trial and Appeal Board that a person of ordinary skill in the art would have enjoyed a reasonable expectation of success in treating non-small cell lung cancer (NSCLC) with erlotinib (OSI Pharmaceuticals LLC v. Apotex Inc., et al., No. 18-1925, Fed. Cir., 2019 U.S. App. LEXIS 29851)....